查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152366

GLP-1受體促效劑和CGM融合市場：規模、佔有率和趨勢分析報告：按產品、應用、連接方式、分銷管道、地區和細分市場預測（2026-2033年）

GLP-1 & CGM Convergence Market Size, Share & Trends Analysis Report By Product (Sensor, Applicator), By Application, By Connectivity (Bluetooth, 4G/Cellular), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 165 Pages | 商品交期: 2-10個工作天內

價格

GLP-1受體促效劑與CGM融合市場概述

預計到 2025 年，GLP-1 受體促效劑與連續血糖監測儀 (CGM) 融合的全球市場規模將達到 16 億美元，到 2026 年將擴大到 18 億美元，到 2033 年將達到 39 億美元，2026 年至 2033 年的年複合成長率（CAGR）。

北美市場佔據主導地位，預計到 2025 年將佔全球銷售額的 84.7%。全球市場正經歷強勁成長，其促進因素包括：糖尿病、肥胖症和代謝健康管理領域交叉領域的不斷擴大；2 型糖尿病患者中 GLP-1 的使用增加；胰島素治療患者群體之外的持續血糖監測 (CGM) 的臨床意識不斷提高；以及對個性化血糖值和生活方式洞察的需求不斷成長。

2026 年美國糖尿病協會 (ADA) 治療指南建議，在成人糖尿病患者中，如果持續血糖監測 (CGM) 有助於治療管理，則應使用 CGM，這進一步提升了 CGM 在 GLP-1 受體激動劑使用者中的臨床意義。同時，非處方 (OTC) CGM 系統的普及降低了使用門檻，使其應用範圍擴大到未接受胰島素治療的患者以及專注於肥胖管理的患者。此外，消費者對即時血糖值反應的認知度不斷提高，也鞏固了 CGM 作為營養管理、運動、體重管理和代謝健康監測輔助工具的地位。

隨著糖尿病和肥胖症的管理日益轉向整合式和數據驅動的方法，基於GLP-1的療法與持續血糖監測（CGM）的融合發展勢頭強勁。 GLP-1受體促效劑和GIP/GLP-1聯合治療可有效控制血糖值、食慾和體重，而CGM則永續可視化血糖值波動模式、治療反應和行為因素。因此，這種聯合療法有望將間歇性HbA1c檢測轉變為持續的個體化代謝管理。 2025年的一篇綜述強調了GLP-1療法與CGM之間的潛在協同作用，尤其是在行為回饋和利用CGM進行個別化監測方面，儘管目前針對非糖尿病肥胖患者的隨機試驗證據仍然有限。

近期真實世界數據進一步強化了聯合應用這兩種技術的臨床合理性。在一項前瞻性研究中，264名接受GLP-1受體激動劑（GLP-1RA）治療但糖化血紅蛋白（HbA1c）未達標的2型糖尿病（T2D）成年患者中，聯合應用瞬時血糖監測的患者組在12個月內HbA1c水平下降了0.58個百分點，而治療了3個百分點，而治療GL0.3個百分點，而治療此外，使用瞬時血糖監測的患者體重減輕幅度也更大，平均減輕約4.0公斤，而GLP-1受體促效劑平均減少2.3公斤。

這項發現尤其重要，因為GLP-1療法並不能取代糖尿病患者進行血糖監測的必要性。 2026年美國糖尿病協會（ADA）治療指南建議，接受胰島素治療的成年糖尿病患者、接受可能導致低血糖的非胰島素治療的患者以及任何需要使用持續血糖監測（CGM）進行血糖管理的糖尿病患者均應使用CGM。指引也允許在難以持續使用CGM的情況下，進行定期自我監測或由專業人員進行CGM監測。

2026 年的更多證據進一步支持了「互補使用」的概念。一項針對 6169 名接受胰島素治療的 2 型糖尿病 (T2D) 成年患者的真實世界基層醫療分析顯示，與單獨接受技術或藥物治療的患者相比，同時接受持續血糖監測 (CGM) 和 GLP-1 療法的患者在糖化血紅蛋白 (HbA1c) 和體重方面均有顯著改善。一年後，聯合治療使 HbA1c 降低了 1.70 個百分點，而單獨使用 CGM 僅降低了 0.85 個百分點，單獨使用 GLP-1 療法僅降低了 1.16 個百分點。雖然接受胰島素治療的這類族群需要更密集的臨床管理，但這項研究進一步證明這兩種介入措施可以產生互補作用。

從市場角度來看，這種整合有望加速CGM從單純的血糖監測設備轉向更廣泛的代謝管理平台的演變。對於第2型糖尿病的GLP-1受體激動劑使用者，CGM可在治療初期、劑量調整、飲食改變和生活方式調整期間提供持續的血糖反應回饋。對於非糖尿病的GLP-1受體激動劑使用者，CGM的應用前景則較偏向消費者。 CGM預計在體重管理計劃中提供飲食、運動、血糖波動和代謝反應方面的回饋。然而，由於目前尚缺乏專門評估CGM與GLP-1受體激動劑聯合用於非糖尿病肥胖患者的隨機對照試驗，因此，後者的這種應用前景應被視為一種新的可能性，而非已在臨床上確立的方案。

這種整合也為GLP-1和CGM整合計畫創造了機遇，這些計畫將藥物治療與血糖數據、營養指導、運動建議、用藥依從性支持和數位健康平台相結合。這可能會鼓勵製藥公司和數位健康服務提供者開發專門針對GLP-1用戶的低成本、短期和簡化的CGM服務，而不是僅依賴傳統的長期CGM模式。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：GLP-1受體促效劑（CGM）的融合市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 結合 GLP-1 受體促效劑和 CGM 的市場分析工具。

第4章：GLP-1受體促效劑與連續血糖監測（CGM）的融合市場：產品特定估算與趨勢分析

  • GLP-1受體促效劑與CGM的融合市場：產品特定趨勢分析
  • GLP-1受體促效劑與CGM的融合市場：產品展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 感應器
  • 施用器
  • 發射機
  • 設備/讀卡器

第5章：GLP-1受體促效劑與連續血糖監測（CGM）的融合市場：按應用分類的估算與趨勢分析

  • GLP-1受體促效劑和CGM的融合市場：按應用領域分類的趨勢分析。
  • GLP-1受體促效劑和CGM的融合市場：依應用領域展望。
  • 市場規模、預測與趨勢分析，2021-2033年
  • 血糖值/糖尿病管理
  • 生活方式監測
  • 飲食和營養監測
  • 監測身體活動和健身
  • 體重管理

第6章：GLP-1受體促效劑與CGM的融合市場：關聯性別評估與趨勢分析

  • GLP-1受體促效劑與CGM的融合市場：連結性趨勢分析
  • GLP-1受體促效劑與CGM的融合市場：連結性展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • Bluetooth
  • 4G/行動電話
  • NFC

第7章：GLP-1受體促效劑與連續伽瑪射線照相術（CGM）的融合市場：按分銷管道分類的估算和趨勢分析

  • GLP-1受體促效劑和CGM的融合市場：按分銷管道分類的趨勢分析。
  • GLP-1受體促效劑和CGM的融合市場：按分銷管道分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 藥局
  • 電子商務
  • 其他

第8章：GLP-1受體促效劑與連續血糖監測（CGM）的融合市場：區域估算與趨勢分析

  • 區域儀錶板
  • GLP-1受體促效劑與連續血糖監測（CGM）聯合市場的區域市場波動分析
  • GLP-1受體促效劑與連續血糖監測儀（CGM）的融合市場：區域估算與趨勢分析
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
    • 新加坡
    • 馬來西亞
    • 台灣
    • 越南
    • 菲律賓
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業的分類
  • 主要公司簡介
    • Dexcom
    • Abbott Laboratories
    • Medtronic plc
    • Sinocare, Inc.（iCan CGM）
    • GlucoRx Limited（AiDEX, Vixxa）
    • Bionime（RIGHTEST iFree CGM）
    • Nemaura
    • i-SENS, Inc.
Product Code: GVR-4-68041-041-0

GLP-1 & CGM Convergence Market Summary

The global GLP-1 & CGM convergence market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.9 billion by 2033, at a CAGR of 11.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 84.7% in 2025. The global market is experiencing strong growth, driven by the growing intersection of diabetes, obesity, and metabolic-health management, rising GLP-1 use among type 2 diabetes patients, expanding clinical recognition of CGM beyond insulin-treated populations, and increasing demand for personalized glucose and lifestyle insights.

The 2026 ADA Standards of Care recommend CGM for adults with diabetes where it can aid treatment management, strengthening the clinical relevance of CGM among GLP-1 users. Concurrently, the growing availability of OTC CGM systems is reducing access barriers and expanding use among non-insulin-treated and obesity-focused populations, while greater consumer awareness of real-time glucose responses is positioning CGM as a complementary tool for nutrition, exercise, weight management, and metabolic-health monitoring.

The convergence of GLP-1-based therapies and CGM is gaining momentum as diabetes and obesity management increasingly shift toward integrated, data-driven approaches. GLP-1 receptor agonists and dual GIP/GLP-1 therapies provide pharmacological control of glucose, appetite, and body weight, while CGM provides continuous visibility into glucose patterns, treatment response, and behavioral triggers. The combination, therefore, creates an opportunity to move beyond episodic HbA1c assessment toward continuous, personalized metabolic management. A 2025 review highlighted the potential synergy between GLP-1 therapy and CGM, particularly through CGM-enabled behavioral feedback and individualized monitoring, although randomized evidence in people with obesity without diabetes remains limited.

Recent real-world evidence is strengthening the clinical rationale for combining the two technologies. A prospective study of 264 adults with T2D receiving GLP-1RA therapy who had not achieved their HbA1c target found that adding flash glucose monitoring produced a 0.58 percentage-point reduction in HbA1c versus 0.35 percentage points with GLP-1RA alone over 12 months. Weight reduction was also greater among patients using flash glucose monitoring, at approximately 4.0 kg versus 2.3 kg with GLP-1RA alone.

The findings are particularly relevant because GLP-1 therapy does not eliminate the need for glucose monitoring in patients with diabetes. The 2026 ADA Standards of Care recommend CGM for adults with diabetes on insulin, on non-insulin therapies that can cause hypoglycemia, and on any diabetes treatment where CGM aids management. The guidelines also recognize periodic personal or professional CGM when continuous use is not feasible.

Additional evidence from 2026 further supports the concept of complementary use. A real-world primary-care analysis of 6,169 adults with insulin-treated T2D found that patients receiving both CGM and GLP-1 therapy experienced the largest improvements in HbA1c and body weight compared with either technology/pharmacotherapy alone. At one year, HbA1c declined by 1.70 percentage points with combination therapy, compared with 0.85 points with CGM and 1.16 points with GLP-1 therapy alone. While this population is insulin-treated and therefore represents a more clinically intensive segment, it provides additional evidence that the two interventions can have complementary effects.

From a market perspective, the convergence could accelerate the evolution of CGM from a predominantly glucose-monitoring device into a broader metabolic-management platform. For GLP-1 users with T2D, CGM can provide continuous feedback on glucose response during treatment initiation, dose titration, dietary changes, and lifestyle modification. For GLP-1 users without diabetes, the opportunity is more consumer-oriented: CGM can potentially provide feedback on meals, physical activity, glucose variability, and metabolic responses during weight-management programs. However, this latter opportunity should be considered emerging rather than clinically established, as randomized trials evaluating combined CGM and GLP-1 use specifically in obesity without diabetes are still lacking.

The convergence also creates opportunities for integrated GLP-1 + CGM programs, combining pharmacotherapy with glucose data, nutrition coaching, exercise recommendations, adherence support, and digital health platforms. This could encourage manufacturers and digital-health providers to develop lower-cost, shorter-duration, simplified CGM offerings targeted specifically at GLP-1 users, rather than relying exclusively on traditional long-term CGM models.

Global GLP-1 & CGM Convergence Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 & CGM convergence market report based on product, application, connectivity, distribution channel, and region:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Sensor
  • Applicator
  • Transmitter
  • Device / Reader
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Glucose / Diabetes Management
  • Lifestyle Monitoring
  • Diet & Nutrition Monitoring
  • Physical Activity & Fitness Monitoring
  • Weight Management
  • Connectivity Outlook (Revenue, USD Billion, 2021 - 2033)
  • Bluetooth
  • 4G / Cellular
  • NFC
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pharmacies
  • E-commerce
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Thailand
    • Singapore
    • Malaysia
    • Taiwan
    • Vietnam
    • Philippines
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Connectivity
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Connectivity outlook
    • 2.2.4. Distribution Channel outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 & CGM convergence Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. GLP-1 & CGM convergence Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. GLP-1 & CGM convergence Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. GLP-1 & CGM convergence Market: Product Movement Analysis
  • 4.3. GLP-1 & CGM convergence Market by Product Outlook (USD Billion)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Sensor
    • 4.5.1. Sensor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Applicator
    • 4.6.1. Applicator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Transmitter
    • 4.7.1. Transmitter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Device / Reader
    • 4.8.1. Device / Reader Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. GLP-1 & CGM convergence Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. GLP-1 & CGM convergence Market: Application Movement Analysis
  • 5.3. GLP-1 & CGM convergence Market by Application Outlook (USD Billion)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Glucose / Diabetes Management
    • 5.5.1. Glucose / Diabetes Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Lifestyle Monitoring
    • 5.6.1. Lifestyle Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Diet & Nutrition Monitoring
    • 5.7.1. Diet & Nutrition Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Physical Activity & Fitness Monitoring
    • 5.8.1. Physical Activity & Fitness Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.9. Weight Management
    • 5.9.1. Weight Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. GLP-1 & CGM convergence Market: Connectivity Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. GLP-1 & CGM convergence Market: Connectivity Movement Analysis
  • 6.3. GLP-1 & CGM convergence Market by Connectivity Outlook (USD Billion)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Bluetooth
    • 6.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. 4G / Cellular
    • 6.6.1. 4G / Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.7. NFC
    • 6.7.1. NFC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. GLP-1 & CGM convergence Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. GLP-1 & CGM convergence Market: Distribution Channel Movement Analysis
  • 7.3. GLP-1 & CGM convergence Market by Distribution Channel Outlook (USD Billion)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Pharmacies
    • 7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. E-commerce
    • 7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Others
    • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. GLP-1 & CGM convergence Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Regional GLP-1 & CGM convergence Market Movement Analysis
  • 8.3. GLP-1 & CGM convergence Market: Regional Estimates & Trend Analysis by Product & Source
  • 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 8.5. North America
    • 8.5.1. North America GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. U.S.
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement scenario
      • 8.5.2.5. U.S. GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Canada
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement scenario
      • 8.5.3.5. Canada GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement scenario
      • 8.5.4.5. Mexico GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Europe
    • 8.5.6. Europe GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. UK
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement scenario
      • 8.5.7.5. UK GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Germany
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement scenario
      • 8.5.8.5. Germany GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. France
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement scenario
      • 8.5.9.5. France GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.10. Italy
      • 8.5.10.1. Key Country Dynamics
      • 8.5.10.2. Competitive Scenario
      • 8.5.10.3. Regulatory Framework
      • 8.5.10.4. Reimbursement scenario
      • 8.5.10.5. Italy GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.11. Spain
      • 8.5.11.1. Key Country Dynamics
      • 8.5.11.2. Competitive Scenario
      • 8.5.11.3. Regulatory Framework
      • 8.5.11.4. Reimbursement scenario
      • 8.5.11.5. Spain GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.12. Russia
      • 8.5.12.1. Key Country Dynamics
      • 8.5.12.2. Competitive Scenario
      • 8.5.12.3. Regulatory Framework
      • 8.5.12.4. Reimbursement scenario
      • 8.5.12.5. Russia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.13. Denmark
      • 8.5.13.1. Key Country Dynamics
      • 8.5.13.2. Competitive Scenario
      • 8.5.13.3. Regulatory Framework
      • 8.5.13.4. Reimbursement scenario
      • 8.5.13.5. Denmark GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.14. Sweden
      • 8.5.14.1. Key Country Dynamics
      • 8.5.14.2. Competitive Scenario
      • 8.5.14.3. Regulatory Framework
      • 8.5.14.4. Reimbursement scenario
      • 8.5.14.5. Sweden GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.15. Norway
      • 8.5.15.1. Key Country Dynamics
      • 8.5.15.2. Competitive Scenario
      • 8.5.15.3. Regulatory Framework
      • 8.5.15.4. Reimbursement scenario
      • 8.5.15.5. Norway GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement scenario
      • 8.6.2.5. Japan GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement scenario
      • 8.6.3.5. China GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement scenario
      • 8.6.4.5. India GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement scenario
      • 8.6.5.5. South Korea GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement scenario
      • 8.6.6.5. Australia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement scenario
      • 8.6.7.5. Thailand GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.8. Singapore
      • 8.6.8.1. Key Country Dynamics
      • 8.6.8.2. Competitive Scenario
      • 8.6.8.3. Regulatory Framework
      • 8.6.8.4. Reimbursement scenario
      • 8.6.8.5. Singapore GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.9. Malaysia
      • 8.6.9.1. Key Country Dynamics
      • 8.6.9.2. Competitive Scenario
      • 8.6.9.3. Regulatory Framework
      • 8.6.9.4. Reimbursement scenario
      • 8.6.9.5. Malaysia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.10. Taiwan
      • 8.6.10.1. Key Country Dynamics
      • 8.6.10.2. Competitive Scenario
      • 8.6.10.3. Regulatory Framework
      • 8.6.10.4. Reimbursement scenario
      • 8.6.10.5. Taiwan GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.11. Vietnam
      • 8.6.11.1. Key Country Dynamics
      • 8.6.11.2. Competitive Scenario
      • 8.6.11.3. Regulatory Framework
      • 8.6.11.4. Reimbursement scenario
      • 8.6.11.5. Vietnam GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.12. Philippines
      • 8.6.12.1. Key Country Dynamics
      • 8.6.12.2. Competitive Scenario
      • 8.6.12.3. Regulatory Framework
      • 8.6.12.4. Reimbursement scenario
      • 8.6.12.5. Philippines GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement scenario
      • 8.7.2.5. Brazil GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement scenario
      • 8.7.3.5. Argentina GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement scenario
      • 8.8.2.5. South Africa GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement scenario
      • 8.8.3.5. Saudi Arabia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement scenario
      • 8.8.4.5. UAE GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement scenario
      • 8.8.5.5. Kuwait GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Dexcom
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Product Benchmarking
      • 9.2.1.4. Strategic Initiatives
    • 9.2.2. Abbott Laboratories
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Product Benchmarking
      • 9.2.2.4. Strategic Initiatives
    • 9.2.3. Medtronic plc
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Product Benchmarking
      • 9.2.3.4. Strategic Initiatives
    • 9.2.4. Sinocare, Inc. (iCan CGM)
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Product Benchmarking
      • 9.2.4.4. Strategic Initiatives
    • 9.2.5. GlucoRx Limited (AiDEX, Vixxa)
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Financial Performance
      • 9.2.5.3. Product Benchmarking
      • 9.2.5.4. Strategic Initiatives
    • 9.2.6. Bionime (RIGHTEST iFree CGM)
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Product Benchmarking
      • 9.2.6.4. Strategic Initiatives
    • 9.2.7. Nemaura
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Product Benchmarking
      • 9.2.7.4. Strategic Initiatives
    • 9.2.8. i-SENS, Inc.
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Financial Performance
      • 9.2.8.3. Product Benchmarking
      • 9.2.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 4. Global GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 5. Global GLP-1 & CGM convergence Market, by Connectvity, 2021 - 2033 (USD Billion)
  • Table 6. Global GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 7. North America GLP-1 & CGM convergence Market, by Country, 2021 - 2033 (USD Billion)
  • Table 8. North America GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 9. North America GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 10. North America GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 11. North America GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 12. U.S. GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 13. U.S. GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 14. U.S. GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 15. U.S. GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 16. Canada GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 17. Canada GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 18. Canada GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 19. Canada GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 20. Mexico GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 21. Mexico GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 22. Mexico GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 23. Mexico GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 24. Europe GLP-1 & CGM convergence Market, by Country, 2021 - 2033 (USD Billion)
  • Table 25. Europe GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 26. Europe GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 27. Europe GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 28. Europe GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 29. Germany GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 30. Germany GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 31. Germany GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 32. Germany GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 33. Spain GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 34. Spain GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 35. Spain GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 36. Spain GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 37. UK GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 38. UK GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 39. UK GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 40. UK GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 41. Italy GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 42. Italy GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 43. Italy GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 44. Italy GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 45. France GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 46. France GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 47. France GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 48. France GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 49. Denmark GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 50. Denmark GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 51. Denmark GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 52. Denmark GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 53. Sweden GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 54. Sweden GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 55. Sweden GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 56. Sweden GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 57. Norway GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 58. Norway GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 59. Norway GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 60. Norway GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 61. Russia GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 62. Russia GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 63. Russia GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 64. Russia GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 65. Asia Pacific GLP-1 & CGM convergence Market, by Country, 2021 - 2033 (USD Billion)
  • Table 66. Asia Pacific GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 67. Asia Pacific GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 68. Asia Pacific GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 69. Asia Pacific GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 70. India GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 71. India GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 72. India GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 73. India GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 74. Japan GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 75. Japan GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 76. Japan GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 77. Japan GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 78. China GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 79. China GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 80. China GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 81. China GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 82. Australia GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 83. Australia GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 84. Australia GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 85. Australia GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 86. South Korea GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 87. South Korea GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 88. South Korea GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 89. South Korea GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 90. Thailand GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 91. Thailand GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 92. Thailand GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 93. Thailand GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 94. Singapore GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 95. Singapore GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 96. Singapore GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 97. Singapore GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 98. Malaysia GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 99. Malaysia GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 100. Malaysia GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 101. Malaysia GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 102. Taiwan GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 103. Taiwan GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 104. Taiwan GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 105. Taiwan GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 106. Philippines GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 107. Philippines GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 108. Philippines GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 109. Philippines GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 110. Vietnam GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 111. Vietnam GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 112. Vietnam GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 113. Vietnam GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 114. Latin America GLP-1 & CGM convergence Market, by Country, 2021 - 2033 (USD Billion)
  • Table 115. Latin America GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 116. Latin America GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 117. Latin America GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 118. Latin America GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 119. Argentina GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 120. Argentina GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 121. Argentina GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 122. Argentina GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 123. Brazil GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 124. Brazil GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 125. Brazil GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 126. Brazil GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 127. Middle East & Africa GLP-1 & CGM convergence Market, by Country, 2021 - 2033 (USD Billion)
  • Table 128. Middle East & Africa GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 129. Middle East & Africa GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 130. Middle East & Africa GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 131. Middle East & Africa America GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 132. Saudi Arabia GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 133. Saudi Arabia GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 134. Saudi Arabia GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 135. Saudi Arabia GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 136. South Africa GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 137. South Africa GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 138. South Africa GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 139. South Africa GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 140. UAE GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 141. UAE GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 142. UAE GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 143. UAE GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)
  • Table 144. Kuwait GLP-1 & CGM convergence Market, by Product, 2021 - 2033 (USD Billion)
  • Table 145. Kuwait GLP-1 & CGM convergence Market, by Application, 2021 - 2033 (USD Billion)
  • Table 146. Kuwait GLP-1 & CGM convergence Market, by Connectivity, 2021 - 2033 (USD Billion)
  • Table 147. Kuwait GLP-1 & CGM convergence Market, by Distribution Channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1. Information procurement
  • Fig. 2. Primary research pattern
  • Fig. 3. Market research approaches
  • Fig. 4. Value chain-based sizing & forecasting
  • Fig. 5. Market formulation & validation
  • Fig. 6. GLP-1 & CGM convergence market segmentation
  • Fig. 7. Market driver analysis (Current & future impact)
  • Fig. 8. Market restraint analysis (Current & future impact)
  • Fig. 9. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10. Porter's Five Forces Analysis
  • Fig. 11. GLP-1 & CGM convergence market, product outlook key takeaways (USD Billion)
  • Fig. 12. GLP-1 & CGM convergence market: product movement analysis (USD Billion), 2025 & 2033
  • Fig. 13. Sensor market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 14. Applicator market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 15. Transmitter market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 16. Device/ Reader market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17. GLP-1 & CGM convergence market, application outlook key takeaways (USD Billion)
  • Fig. 18. GLP-1 & CGM convergence market: application movement analysis (USD Billion), 2025 & 2033
  • Fig. 19. Glucose / Diabetes Management market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20. Lifestyle Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21. Diet & Nutrition Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22. Physical Activity & Fitness Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23. Weight Management market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 24. GLP-1 & CGM convergence market, connectivity outlook key takeaways (USD Billion)
  • Fig. 25. GLP-1 & CGM convergence market: connectivity movement analysis (USD Billion), 2025 & 2033
  • Fig. 26. Bluetooth market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27. 4G / Cellular market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28. NFC market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29. GLP-1 & CGM convergence market, distribution channel outlook key takeaways (USD Billion)
  • Fig. 30. GLP-1 & CGM convergence market: distribution channel movement analysis (USD Billion), 2025 & 2033
  • Fig. 31. Pharmacies market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 32. E-commerce market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 33. Others market revenue estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34. GLP-1 & CGM convergence market, regional key takeaways (USD Billion)
  • Fig. 35. GLP-1 & CGM convergence market regional outlook, 2025 & 2033, USD Billion
  • Fig. 36. North America GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 37. U.S. GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38. Canada GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 39. Mexico GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40. Europe GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41. UK GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 42. Germany GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43. France GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 44. Italy GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45. Spain GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 46. Russia GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47. Denmark GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 48. Sweden GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49. Norway GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 50. Asia Paciifc GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 51. Japan GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 52. China GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53. India GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 54. Australia GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55. South Korea GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 56. Thailand GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57. Singapore GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58. Malaysia GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 59. Taiwan GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 60. Vietnam GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 61. Philippines GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 62. Latin America GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 63. Brazil GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 64. Argentina GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 65. Middle East & Africa GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 66. South Africa GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 67. Saudi Arabia GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 68. UAE GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 69. Kuwait GLP-1 & CGM convergence market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 70. List of key emerging company's/indication disruptors/innovators